Several studies have reported that patients with p53-altered bladder cancer benefited from adjuvant chemotherapy [44], whereas wild-type p53 was related to a poor response to systemic cisplatin-based chemotherapy [45], which might be related to the protection of cells from DNA damage by wild-type p53. Here, TP53 is linked to urinary bladder cancer.